



Changing cancer care together

# 4

## All.Can at four years: annual report 2020

All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol Myers Squibb (main sponsor), Roche (major sponsor), MSD and Johnson & Johnson (sponsors) and Baxter and Illumina (contributors), with additional non-financial (in kind) support from Helpsy, Intacare and Goings-On.

# All.Can International

All.Can is an international, multi-stakeholder not-for-profit organisation working to improve the efficiency of cancer care by focusing on what matters to patients.

All.Can comprises leading representatives from patient organisations, policymakers, healthcare professionals, research and industry, and consists of All.Can International and All.Can National Initiatives.




## Section 01

### All.Can's Objectives



Generate evidence and new data to inform policy



Advance impact metrics to scale up efficient care practices



Engage stakeholders and co-create policy and sustainable care solutions



Drive policy change by embedding All.Can recommendations into cancer control plans



Build and leverage partnerships and conduct joint projects



Continue to establish All.Can as the go-to initiative on cancer care efficiency

# Contents

Section 01	All.Can International .....	2	Section 06	Vision and Mission .....	14
Section 02	Foreword .....	4	Section 07	Efficiency Definition .....	15
Section 03	Highlights in 2020 .....	6	Section 08	Projects .....	16
Section 04	Governance .....	8	Section 09	All.Can International Members .....	18
Section 05	All.Can in the Media .....	13	Section 10	All.Can National Initiatives .....	19

# Foreword

**2020 has been a challenging year and the global COVID-19 pandemic is changing our world significantly. Despite this, All.Can International has continued to expand its work and strengthen its organisation to inform positive policy evolution towards more efficient cancer care and better health outcomes.**

In the fourth year of its existence, All.Can accomplished an important step in deepening its credibility and external recognition by acquiring legal status as a not-for-profit organisation registered in Belgium. Accompanied by the appointment of a dedicated Chief Executive Officer, as well as a Secretariat, this milestone marked a consolidation for All.Can and underpinned our members' commitment to continue working in partnership to help achieve All.Can's mission.

A broad consultation with members was carried out to establish a strategic framework for All.Can and formulate a concrete plan of action. As an immediate result, a task force was created to review and develop All.Can's holistic definition of 'efficiency in cancer care'. The agreed definition will be translated into a compact, visual document.

With the guidance of the All.Can (Interim) Board, the three Working Groups have conducted their respective work programmes under the leadership of newly appointed Co-Chairs, and are tackling the organisation's specific activities in the areas of research and evidence, external policy engagement, as well as strengthening collaboration amongst All.Can's National Initiatives across the globe.

All.Can continues to grow and expand its reach, counting 26 members and 16 National Initiatives at the end of 2020, and interacting with numerous

important stakeholders and institutions relevant in the cancer sphere, such as UICC, SPCC, IPAAC, ECO, ECPC and the European Institutions. All.Can's greatest strength is its multi-stakeholder partnership represented by patient advocates, healthcare professionals, industry representatives, academics and researchers alike, who together strive to improve the efficiency of cancer care by focusing on what matters most to patients.

The global COVID-19 pandemic has created unprecedented challenges for healthcare systems worldwide in this past year. During the first wave of spring 2020, WHO found that 42% of countries had partially or completely disrupted cancer services due to COVID-19.<sup>1</sup>

Now more than ever we need to raise our voice to promote health system efficiency and maintain cancer care continuity. All.Can, through its multidisciplinary membership, will pursue its aim to ensure that resources are directed towards achieving better health outcomes for cancer patients, while contributing to overall sustainability of our health systems.

1. <https://www.who.int/news/item/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases>



Alex Filicevas  
President,  
All.Can International



Eduardo Pisani  
Chief Executive Officer,  
All.Can International



**“With the pressure of increasing cancer incidences worldwide, compounded by the on-going pandemic, healthcare systems and society face unprecedented challenges. I am proud of what All.Can has achieved in just 4 years and I am enthusiastic about our future progress together with the All.Can global community, as we continue to drive evidence-based policies, and improve efficiency, equity and sustainability of cancer care for better patient and societal outcomes”.**

**Titta Rosvall-Puplett**  
Bristol Myers Squibb, Vice President of the Board  
and Co-founder of All.Can International



**All.Can’s homepage says: “We imagine a world in which patients are always at the heart of cancer care”. In 2020 we all had to face the COVID-19 crisis. Our health systems were disrupted, with terrible consequences for early diagnosis, and some treatments, for cancer patients and many others. In 2021 we should be wiser, having learned, and the patient will be at the centre of care, in all settings, hopefully as a citizen and not as a patient because prevention (in some cases through vaccination) will have avoided disease.**

**Matti Aapro**  
Clinique de Genolier / European Cancer Organisation, Vice  
President of the Board and Co-founder of All.Can International





# Highlights in 2020

Jan

- New CEO and Secretariat hired

- All.Can Policy Forum 'Sustainable cancer care in Europe: building on patient insights and best practice' at European Parliament

Feb

Mar

- Response to Europe's Beating Cancer Plan roadmap

- All.Can joins the EU Health Coalition

Jun

May

- Response to Europe's Beating Cancer Plan public consultation

Apr

- Statement regarding the continuity of cancer care during the COVID-19 pandemic

- Statement on European Patients' Rights Day



Jul

- All.Can strategic planning session

Aug

- Collaboration with UICC on its master course on patient engagement

Sep

- Proposal for the fostering of implementation research in the EU Cancer Mission

Oct

- Collaboration with SPCC on joint webinar series 'Spotlights on Improving Efficiency in Cancer Care'

Nov

- All.Can speaking on achieving better outcomes for patients at World Cancer Series Europe

Dec

- All.Can Korea is established as 16th National Initiative

# Governance


## All.Can Legal Entity

In early May, All.Can was formally incorporated as not-for-profit organisation (ASBL) in Belgium, with its legal seat in Brussels.

Launched in December 2016 as a multi-stakeholder initiative, this next step in All.Can’s development marked a milestone for the organisation, enhancing transparency and credibility towards public institutions and other organisations, with a view to further expanding the organisation’s outreach and collaboration with relevant partners.

Building on three years of success since the inception, acquiring legal status demonstrates the commitment of All.Can’s multi-stakeholder members to continue working in partnership, striving to improve the efficiency of cancer care by focusing on what matters to patients.

All.Can International acknowledges and is grateful to Freshfields for the legal advice provided on a pro bono basis during this legal setup phase.





## Board of Directors

The Board of Directors carries the legal responsibility and governing power of All.Can international. It gives directional guidance and ratifies the overall strategy, provides planning and oversight, governance, and policies, and engages in promotion and representation.

Following the incorporation as a legal entity in May 2020, All.Can International has been led by an interim Board of Directors, representing the different stakeholder groups of the organisation. The first elections will be held in early 2021 and the Board will take office at the Annual General Meeting of 2021.



**Alex Filicevas,**  
President  
World Bladder Cancer  
Patient Coalition



**Dr. Matti Aapro,**  
Vice-President  
Clinique de Genolier



**Titta Rosvall-Puplett,**  
Vice-President  
Bristol Myers Squibb



**Caroline Falciola,**  
Task Force Co-Chair  
Roche



**Borna Müller,**  
Task Force Co-Chair  
Roche

### Ad-Hoc Task Force on Efficiency in Cancer Care

A dedicated task force, composed of ten individuals representing All.Can's multi-stakeholder membership, has been working on a new definition of 'efficiency in cancer care' which will underpin all of All.Can's future work and publications. Further to an internal consultation with members, the task force sought external advice and validation from multidisciplinary experts in their fields. The All.Can definition of efficiency will be introduced to All.Can's partners and cancer policy stakeholders in 2021.

## Research and Evidence Working Group

The Research and Evidence Working Group plays a strategic role in identifying, developing, and supervising the execution of new research projects to support All.Can's goal of generating robust evidence to inform cancer policies locally and globally. It uses research and evidence to constantly refine and update the definition and measurement of cancer care efficiency and support All.Can's external engagement and dissemination activities, oversees, updates and scales up opportunities as listed in the All.Can Efficiency Hub (<https://www.all-can.org/efficiency-hub/>) and ensures scientific rigor and policy applicability of All.Can's findings and recommendations.



**"All.Can is providing strategies on how we can improve cancer care and valuable insights into what matters most to patients. As a clinician and researcher, I find the real-world examples of efficient care particularly useful, and I am delighted at the impact the organisation is beginning to make in developing sound policy in cancer care globally."**

**Christobel Saunders**  
University of Western Australia, Co-Chair of the All.Can Research and Evidence Working Group



**"As an international organisation All.Can plays an essential role in performing quality research and developing real-world, evidence-based strategies to promote the delivery of patient-centric, evidence-based and sustainably affordable cancer care that can be adopted locally and internationally. As a healthcare professional, researcher and senior cancer care commissioner, I find All.Can's approach refreshing and I am excited by the impact All.Can is having on the design and delivery of well-considered improvements in cancer care globally."**

**Matt Hickey**  
Intacare, Co-Chair of the All.Can Research and Evidence Working Group



## Public Affairs Working Group

The Public Affairs Working Group determines All.Can's external policy engagement activities, explores strategic partnerships, and defines its advocacy actions and communications with a view to engaging stakeholders and driving policy change.



**"Cancer is one of the greatest challenges the world faces today. It is therefore crucial for all sectors to join forces to eliminate inefficiency in cancer care. Through its external engagement activities, All.Can defines targeted actions towards shaping the international policy landscape and explores strategic partnerships to make this happen."**

Adela Maghear  
European Cancer Patient Coalition,  
Co-Chair of the All.Can Public Affairs Working Group



**"We have the ambition to extend and improve the lives of people with cancer. For change to be meaningful and lasting, we need meaningful and lasting collaboration. All.Can provides the structural platform that enables dialogue, identifies solutions and drives action between and with all stakeholders that share this ambition with us."**

Matthijs Van Meerveld  
MSD, Co-Chair of the All.Can Public Affairs Working Group



## National Initiatives Working Group

The National Initiatives Working Group aims to facilitate collaboration between All.Can’s National Initiatives with a view to exchanging and promoting expertise and best practice, creating multinational projects, and strengthening All.Can’s global presence through a network of engagement and thought-leadership.



**“The 16 National Initiatives, now part of the All.Can family, are an essential element of our collective success, with ambition and commitment to drive change in their countries. Tackling inefficiency in cancer care, we benefit from each other’s expertise, learning from unique solutions whilst bringing best-practices across borders. Together, we can lead the way towards improving cancer care for patients and the long-term sustainability of our healthcare systems, which is now more urgent than ever.”**

**Alex Filicevas**  
World Bladder Cancer Patient Coalition, President of the All.Can Board, Co-Chair of the All.Can National Initiatives Working Group and Co-Founder of All.Can International



**“Over the past year, All.Can has become a truly global movement, with National Initiatives starting up in every region of the world including Asia and Latin America. While problems of inefficiency may be similar across the world, the solutions to those problems may be unique to each country. Together, All.Can National Initiatives are tackling inefficiency in cancer care at country level, where the real change happens.”**

**Sara Martin**  
Bristol Myers Squibb, Co-Chair of the All.Can National Initiatives Working Group



# All.Can in the Media

All.Can was featured in the article "Life after COVID-19: R WE going to help?" by Sreeram V. Ramagopalan & Radek Wasiak which was published on 11 May 2020 in the *Journal of Comparative Effectiveness Research*.

To mark the European Week Against Cancer and the Croatian Presidency of the Council of the European Union, the Croatian Pharmaceutical Society (Hrvatsko farmaceutsko društvo (HFD)) published a "Questions & Answers" with All.Can International's CEO in its publication *PRIME Oncology*.

An article and interview with All.Can's CEO, entitled "Efficient cancer care meeting highest patient needs produce best treatment results" was published on 15 January 2021 in the *Korea Biomedical Review* in light of the launch of the All.Can National Initiative in Korea.

All.Can continued to grow its presence on social media, now counting more than 1000 followers on Twitter, 350 on LinkedIn and 270 on Facebook.



350  
followers



270  
followers



1000  
followers

# Vision and Mission

In 2020, a strategic review of All.Can's activities was undertaken in collaboration with the membership, which set out an updated vision and mission, providing strategic direction for the organisation in the years ahead. Ambitious and realistic objectives were defined and translated into tactical action in the form of an action plan.



# All.Can's Definition of Efficient Cancer Care

## What is efficient cancer care?

Efficient cancer care delivers the best possible health outcomes using the human, financial, infrastructural and technological resources available, with a focus on what really matters to patients and society.

## Why do we need to improve cancer care efficiency?

For cancer patients, healthcare inefficiencies can lead to **premature mortality, reduction in quality of life, financial and time losses, and inequities** between different groups in society.

Inefficiencies can **demoralise and frustrate care providers**, who feel unable to give optimal care to their patients

Inefficiencies weaken health systems, services and processes: they lead to **significant financial loss and missed opportunities**, and hamper the freeing up of resources that could bring continuous improvement to healthcare systems.

Inefficient healthcare systems are **less resilient, less adaptive and less innovative**.

## How can we achieve greater efficiency in cancer care?

### Put the patient at the centre

Ensure that the patient perspective is the main determinant when defining health outcomes that matter, in line with the concept of Value-Based Healthcare.

### Promote an evidence-based and data-driven learning system

Define key outcomes and quality/performance indicators through multi-stakeholder collaboration, and evaluate data generated in terms of health outcomes achieved in relation to resources spent.

### Invest in technology

Identify, assess and adopt diagnostics and digital tools that improve health outcomes, and invest in digital innovations that support care provision and coherent use of health data.

### Break down silos

Foster efficiency through a cross-silo approach spanning the entire health system.

### Scale up good practices

Champion efficient and innovative cancer practices and retire ineffective, duplicative, harmful and/or wasteful cancer interventions.

### Support healthcare professionals and providers

Give healthcare professionals and providers the opportunity to learn how to improve efficiency in cancer care.

### Implement appropriate policies and incentives

Policymakers at all levels of decision-making should implement suitable legislative frameworks, policies and incentives to foster efficiency and include clear, pragmatic goals for improving cancer patients' outcomes.



Section  
07

# Projects

## Efficiency Hub

All.Can continues to gather examples of best practice in cancer care from its growing network, providing value to the cancer care community by creating a learning community around efficient practices, helping organisations to find and implement solutions to common challenges. Showcased in the Efficiency Hub online (<https://www.all-can.org/efficiency-hub/>), these best-practice examples are readily accessible to all, covering the entire cancer care pathway, from prevention and screening to treatment and follow-up care, end-of-life care and survivorship, as well as all tumour types. There are currently 18 best practices showcased in the Efficiency Hub, with more added frequently.

Furthermore, in light of the pandemic, a dedicated webpage compiling articles and resources on COVID-19 has been made available on the website.

## The Role of Data

Work on the development of the report “What is the role of data in driving efficiency in cancer care?”, which will outline the role of different data sources in driving efficiency, highlight key opportunities and challenges, and give recommendations for actions, continued to progress in 2020. Based on expert insights, literature reviews, case studies and best practice examples, the report will take a forward-looking view on how health care systems and policy frameworks should evolve to enable data to drive efficiency in cancer care. The report will be launched in the first half of 2021.





## CME-Accredited Webinars for HCPs

All.Can collaborates in a series of monthly webinars 'Spotlights on improving efficiency in cancer care' promoted by Sharing Progress in Cancer Care (SPCC).

Kicked off in December 2020, the CME-accredited webinar programme is composed of the following essential elements, aiming at content development to underpin the delivery of efficient cancer care:

- An international educational curriculum addressed to HCPs;
- An outreach and advocacy programme towards policymakers and key stakeholders;
- An academic analysis (methodology and impact assessment).

## All.Can Policy Position

The All.Can Public Affairs working group has been working on a Policy Report, which will be published in the first half of 2021.

The report will explain how to improve efficiency in practice, showcase examples from the All.Can Efficiency Hub, members and National Initiatives, and provide policy recommendations to help improve efficiency of cancer care.

Sharing Progress in Cancer Care is pleased to invite you to its first webinar of the series  
Spotlights on Improving Efficiency in Cancer Care

### What is Efficiency in Cancer Care?



EXPERT

*Alex Filicev*

All.Can International and World  
Bladder Cancer Patient Coalition  
Brussels, Belgium



EXPERT

*Stefan Gijssels*

Digestive Cancers Europe  
Overijse, Belgium



EXPERT

*Eduardo Pisani*

All.Can International  
Brussels, Belgium



DISCUSSANT

*Pietro Presti*

Sharing Progress in Cancer Care  
Turin, Italy

**1st December from 18:00 to 19:10 CET**

via [www.spcc.net](http://www.spcc.net)

# All.Can International Members

All.Can International's membership reflects its multi-stakeholder representation and includes experts from patient organisations, policymakers, healthcare professionals, researchers and industry.

Currently counting 26 organisational members, All.Can continues to reach out and engage with a variety of healthcare organisations with a view to expanding its international membership.

All.Can receives funding from six industry partners: Bristol Myers Squibb (main sponsor), Roche (major sponsor), MSD and Johnson & Johnson (sponsors), Baxter and Illumina (contributors).

In addition, three knowledge partners, Helpsy, Intacare and Goings-On provide in-kind support to All.Can.



# All.Can National Initiatives

While issues of inefficiency in cancer care may be universal, All.Can understands that every country faces its own barriers and challenges – resulting in the need for unique solutions around the globe. Together with its National Initiatives, All.Can brings meaningful change worldwide to cancer patients at an individual level.

National Initiatives address local challenges in cancer care by bringing stakeholders together, identifying the needs of local healthcare systems and shaping national healthcare environments by implementing solutions into national cancer plans and policies. Acting as a hub, All.Can International All.Can connects the National Initiatives and shares examples of success and best practice from around the world.

Approved and regularly reviewed by the All.Can International Board, the multi-stakeholder National Initiatives follow a coherent and aligned approach to governance and overall transparency. By the end of 2020, National Initiatives have been launched in 16 countries, accounting for nearly 150 stakeholders brought together under the All.Can umbrella across the globe. The most recent addition has been Korea, having joined in December 2020 as first National Initiative in Asia. Further launches are planned in 2021 in Colombia, Israel and Mexico.

## All.Can National Initiatives' Overall Objectives



**Eliminate inefficiencies in national cancer care pathway and improve overall patient outcomes**



**Contribute to new evidence and development or renewal of national cancer control plans and related policies**



**Build strategic alliances with leading national cancer stakeholders and policy-makers**



**Position All.Can as a thought-leader in national cancer policy**

# Argentina





## Achievements 2020

In 2020, All.Can Argentina carried out a Cancer Patient Survey in which 400 patients of the Buenos Aires Metropolitan Area, were canvassed. The research, which also had a qualitative component, revealed inequities in access to treatment, delays from the time of detection, as well as the disease's heavy emotional and personal financial impact. The survey methodology included 40-minute face-to-face or telephone interviews with patients from public health services and those with prepaid health insurance. Significantly, the survey showed that in Argentina, cancer diagnosis is on average delayed for six months from the onset of symptoms.

## Outlook 2021

All.Can Argentina's work in 2021 will be focused on projects formulated around the main results of the Patient's Survey. The projects, to be tailored towards the needs of patients shown in the survey results, include a training programme on oncology for primary care physicians and a training programme on information-sharing skills for oncologists together with a national medical university. Throughout the year, a series of round table discussions on the survey's results will be organised with key stakeholders and policymakers.



# Australia

## Achievements 2020

To mark its third year, All.Can Australia initiated a project to analyse the economic and patient impact of Cancer Care Navigators, with the goal to help people with cancer better navigate the Australian health system. Results from All.Can Australia's report "An Exploration of the Cancer Pathway in Australia" showed that cancer patients and their families experience confusion and distress at every stage in the Australian health care path, emphasising the need for developing a Cancer Care Navigator role to support patients throughout their journey. All.Can Australia partnered with Healthcare Management Advisors (HMA) to implement a multi-stage project. The role of the Navigator has been defined and a vision statement agreed, and evidence on costs, benefits, effectiveness and economic outcomes gathered.

## Outlook 2021

All.Can Australia will continue its work on the Cancer Care Navigator project, and assess the economic viability of the model and explore funding opportunities to support a


national rollout in the future. With additional support, All.Can Australia will also seek to trial the proposed model in a small-scale controlled setting. The findings from this pilot project will inform the project's advocacy activity with Australian health policymakers.

All.Can Australia also plans to explore the possibility of developing a project to assist with inefficiencies experienced at the diagnosis stage. According to the 2019 All.Can global patient survey, 23% of Australian respondents identified the initial diagnosis phase as the most inefficient one in their journey.

Finally, All.Can Australia will be founded as an independent not-for-profit entity to ensure its long-term success and support.



# Austria



## Achievements 2020

In 2020 All.Can Austria developed a framework which creates evidence for further development of cancer care in Austria, based on modern concepts including health in all policies, social determinants of health and an evidence-based goal setting.

Members of the All.Can Steering Committee and the Karl Landsteiner Society supported the foundation of an independent Alliance of Oncological Patient Organisations in Austria, which aims to strengthen the position of cancer patients in the country by promoting professional patient advocacy and continuing education.


Another All.Can Austria project, conducted in collaboration with the Medical University of Vienna and hospitals throughout Austria, evaluates the effectiveness and efficiency of Tumor Boards to improve patient outcomes.

The aims of All.Can Austria were presented and published at the 16th World Congress on Public Health, hosted by the European Public Health Association and the World Federation of Public Health Associations.

## Outlook 2021

All.Can Austria will be part of an event on patient perspectives and consequences of COVID-19 on cancer care, hosted by the Landsteiner Society and the Alliance of Oncological Patient Organisations. All.Can Austria's kick-off event is planned in autumn 2021.

In addition, All.Can Austria will implement an Austria-specific scientific-based patient survey and further intensify its work to identify additional projects, while strengthening its governance and structure to attract supporters for the initiative.





# Belgium

## Achievements 2020

Despite the challenges of working through the COVID-19 pandemic, All.Can Belgium continued to promote and protect cancer patients' needs while growing and strengthening its position both in the media and in the political arena. A press statement was distributed widely and picked up by mainstream media in April 2020 to raise awareness on the impact of COVID-19 on Belgian cancer patients and the subsequent delays to treatments, consultations, and screenings. All.Can Belgium publicly urged the government to resume oncological care as soon as possible and offered its expertise to the group of experts in charge of the national pandemic response.

In May, the initiative's co-chairs were invited to discuss practical solutions to mitigate the impact of COVID-19 on cancer patients with the cabinet of the Federal Minister of Health. A memo outlining 10 key steps to optimise and guarantee safe cancer care was produced by All.Can Belgium and will be used as basis for future collaboration with policymakers.

## Outlook 2021

All.Can Belgium became funder and partner of the research project "OPTIMOC" (Optimisation of Multidisciplinary Oncology Consultation in Belgian Oncology Departments), which was officially launched in January 2021 and aims to improve patient-centred treatment decision-making for cancer patients.

Another project will be launched to promote the awareness and importance of early diagnosis amongst younger patients, especially in the case of testicular and breast cancer. Informing younger patients, their families, as well as doctors across all disciplines about the early signs and symptoms to shift diagnosis to an earlier cancer stage will improve treatment outcomes and save more young patients' lives.





# Canada

## Achievements 2020

In February 2020, All.Can Canada published “Consolidated Report of Waste and Inefficiency in Canadian Cancer Care: Multi-Stakeholder Insights and Recommendations”, which was disseminated widely among cancer care stakeholders and Canadian patient groups.

In addition, COVID-19 impact surveys were undertaken in collaboration with fellow patient groups. All.Can Canada also facilitated the creation of the COVID-19 Cancer Patient Support Hub, made up of a task force of 14 Canadian oncology patient groups. This bilingual online hub provides information, mental health resources and wellness and practical support. It has received over 7,000 requests for help since its launch. The hub’s free taxi service has provided patient transportation to medical appointments in Montreal and Toronto, and hundreds of patients have attended the hub’s Mindfulness@Home online self-help series.

All.Can Canada also kicked off a research project entitled “Environmental Scan: Optimising Entry into Canadian Cancer Care Systems, Ensuring Swift, Accurate and Appropriately Delivered Diagnoses”. The


research plan, literature review and patient interviews had been completed at the end of the year.

## Outlook 2021

In 2021, All.Can Canada will maintain the COVID-19 Cancer Patient Support Hub, and complete the Environmental Scan, specifically focusing on the provider survey, collection of best practices and development of the final report, as well as the internal and external communications and engagement plan. The report will be widely disseminated and a multi-stakeholder roundtable meeting will be convened to analyse the findings and develop actionable recommendations and next steps.

MENTAL HEALTH & WELLNESS	FAQS & RESOURCES	PRACTICAL SUPPORT
Access local mental health support for cancer patients including 1-on-1 digital counselling, live online group sessions, digital wellness programs, video and audio resources for guided meditations.	Get reliable information from medical professionals, cancer centres, provincial and federal bodies, and Canadian patient groups related to COVID-19 and oncology.	Find individual support for cancer patients living in Canada who require assistance with access to grocery delivery, subsidized transportation and digital social connectivity.
<a href="#">ACCESS SUPPORT</a>	<a href="#">LEARN MORE</a>	<a href="#">FIND HELP</a>





# Denmark

## Achievements 2020

All.Can Denmark, consisting of policymakers, healthcare professionals, patient organisations, and other leading experts, focuses its work on early diagnosis and equal access to cancer treatment.

Its ambition is to set the agenda in cancer care by creating a strong interdisciplinary multi-stakeholder group and combining visions, research, and day-to-day experiences to address issues and gain insights about cancer care.

All.Can Denmark hosted two digital innovation meetings during which broad groups of stakeholders in the field of Danish cancer research discussed and qualified the ongoing focus on early diagnosis and provided valuable insights to the network. The participants ranged from hospital management staff, to policymakers, physicians and industry representatives.

## Outlook 2021

In early 2021 All.Can Denmark will present its aims in an animated film which will be disseminated widely.

It will be accompanied by increased efforts to create more public awareness of All.Can Denmark's work.

In spring, the Danish Centre for Social Science Research (VIVE) will publish a new extensive report about diagnosing cancer outside the fast-track cancer referral programmes in Denmark, which will include input from All.Can Denmark. It will be used to create political and professional awareness about access to treatment and early diagnosis.

In April, All.Can Denmark will host a national, digital conference: "Cancer Summit: From symptom to diagnosis – how can we create the best course of treatment for cancer patients in Denmark?", which will be live-streamed and used to present the work of All.Can Denmark and create further awareness of the network's efforts. Moreover, All.Can Denmark plans to arrange a physical, political conference to be held by the end of the year.

# Germany

## Achievements 2020

All.Can Germany's Steering Committee was extended to include Members of the German Parliament, as well as stakeholders from cancer care and pharmaceutical sectors.

The main points of discussion have revolved around the state of cancer care in rural Germany. All.Can Germany organised a digital planning meeting for a pilot project that focuses on this topic. In addition, the All.Can Germany initiated an assessment of the current cancer care structures in rural areas and identified needs for further improvement. All.Can Germany worked together with researchers from the University Hospital in Halle (Saale) who are in the process of implementing the results of the assessment independently.

In the second half of 2020, the All.Can Germany conducted several interviews with oncology experts and politicians to investigate cancer survivorship structures in Germany with the objective to publish a report on

recommended actions to improve the situation. The experts were brought together for a roundtable meeting with high-level stakeholders, such as the German Cancer Society, in mid-December.

## Outlook 2021

In 2021 the main focus is to further distribute and implement the courses of action regarding cancer survivorship. In addition to the publication of a detailed report, the secretariat plans to continue to bring together relevant stakeholders, research and cancer care interest groups.





# Greece

## Achievements 2020

In April, All.Can Greece submitted practical policy recommendations to facilitate access to cancer care during the COVID-19 pandemic and to limit the exposure of cancer patients to the risk of infection, calling on the Ministry of Health to adjust the measures to assure that cancer care is provided in a proper and efficient way during the health crisis.

A nationwide survey on cancer patients' experiences relating to care and treatment during the first wave of the pandemic was conducted over the summer, generating valuable results on the pandemic's impact on cancer care and highlighting the problems patients had experienced.

At the end of 2020 All.Can Greece launched its new Greek-language website and a promotional video.

A webinar entitled "Aiming for the best cancer care", which included an introduction of All.Can Greece and a session on the impact of COVID-19 on cancer care, was attended by key stakeholders.

The Universities of Athens and Piraeus, both members of All.Can Greece, were appointed to conduct two major surveys about cancer care in Greece, which will document problems and inefficiencies that result in delays to starting treatment.

## Outlook 2021

All.Can Greece will present the results of its surveys conducted in 2020 at the All.Can Greece event in April. A list of recommendations for improvements in cancer care will be submitted to the Greek Ministry of Health.

Several meetings with local cancer and health care stakeholders will be organised, and at the end of 2021 an All.Can Greece event on prevention will address the importance of screening and early diagnosis, as well as a healthy lifestyle.





# Italy

## Achievements 2020

During the year, All.Can Italy expanded its development work on the 'Proximity Oncology' model and discussed it with its main stakeholders. The model is based on the integration of levels of care, including home care, general practice, and hospital specialist care, as defined by the Integrated Care Pathways and Oncology Networks. It also takes other aspects into account, including how to manage and redistribute the care settings on the basis of constant monitoring of the value of each service, with the focus being centred on the patient's needs.

## Outlook 2021

All.Can Italy will focus on its two main areas of research during the year. With a first project All.Can Italy will seek to address the regional disparities in onco-haematology and look at ways in which they can be reduced, emphasising home care as a good practice.

A second project investigates the new balance in the organisation of care, with an in-depth look at the reform of tertiary care currently in progress. The results will be disseminated to decision-makers in the form of policy proposals.



# Korea

## Achievements 2020

In December 2020, All.Can Korea became the first Asian National Initiative of the All.Can International global network. The official launch was announced at a virtual press conference, during which the results of a survey conducted among 495 cancer patients was released.


The survey assessed the psychological, economic, and social difficulties that patients face during diagnosis, treatment, and post-treatment, and showed that, while psychological support is known to be an essential element of care, patients themselves are unaware of this and are not receiving sufficient assistance. In addition, health inequity occurs at the start of cancer diagnosis depending on patients' socio-economic status, with low-income patients often being diagnosed at more advanced stages of cancer. These inequities in early diagnosis and treatment require greater attention and improvement.

## Outlook 2021

Based on the survey outcomes, All.Can Korea will launch a campaign to improve awareness on the need for psychological support for cancer patients, and

work to find solutions for the inefficiencies in cancer diagnosis for the low-income bracket, while refining and improving the various policies and laws designed to support patients.

To achieve this, All.Can Korea will launch programmes such as the All.Can Korea Forum for discussing the implementation of key projects, a stakeholder workshop on sustainable cancer care, and additional surveys to provide evidence and align with related academic conferences. Domestic cancer research data will be collected and disseminated globally through the All.Can International website, and an 'ideas contest' will be launched to canvas for new actions based on the 2021 agenda.





# Norway

## Achievements 2020

At its public launch in May 2020, All.Can Norway promptly released an awareness campaign presenting the scope of the initiative and its key focus areas. Aiming to encourage politicians and the health care system to increase efforts in “prehabilitation” and “reliable & safe discharge”, six videos were published and disseminated widely in the network.

All.Can Norway collaborated with the Norwegian organisation “Cancer Compass” (Kreftkompasset) on the publication of the book “Every day counts – life after cancer”. Using the stories of eight survivors, the goal of the book is to provide advice and insights into life after a cancer diagnosis.

## Outlook 2021

In 2021, All.Can Norway’s objective is that as many Norwegian cancer patients as possible

receive a copy of the book “Every day counts – life after cancer” once the treatment has been completed.

In addition, All.Can Norway will focus on the areas of “prehabilitation” and “safe and reliable discharge” for patients who have been diagnosed with cancer. The overall goal of the initiative is to influence the political debate so that these core issues are given the necessary priority in Norway’s cancer policy.

### DERFOR STØTTER ALL.CAN NORGE DENNE BOKEN

All.Can Norge er Kreftkompassets hovedsamarbeidspartner på dette bokprosjektet – og vi er veldig stolte over å bidra til utgivelsen av «I hver dag teller».

All.Can ble etablert i 2017 som et internasjonalt initiativ med lokale styringsgrupper. De som står bak All.Can i Norge er: Hjernevitelseforeningen, Lungkreftforeningen, Carcinor (NET-kreftforeningen), Aktiv mot kreft, Roche Norge og Brittel Myers Squibb Norge.

#### Tiden før og etter behandling

Målet vårt er å bidra til en bedre og mer effektiv kreftbehandling i Norge og vi tror denne boken kan gjøre en forskjell i å vise frem hvor viktig det er å bruke tiden riktig – både før og etter kreftbehandlingen.

Vårt ønske er at politikere og helsevesen øker innsatsen på disse to hovedområdene – slik at livet etter kreft blir så godt og langt som mulig for alle pasienter.

#### PREHABILITERING

- Prehabilitering handler om å bruke tiden fra diagnosestidspunkt til behandlingstid best mulig, sammen med pasienten.
- Pasienter som er fysisk og mentalt best mulig forberedt før behandlingen starter får bedre behandlingresultat og raskere rehabilitering etter behandling.
- Trening, kostholdsrådgivning, rykkeslutt og økt kunnskap om behandlingstidspunkt bør tas inn som del av prehabiliteringen.

#### TRYGG UTSKRIVNING

- Alle kreftpasienter som skrives ut må få en tydelig beskatning av sin individuelle oppfølging og vei videre i helsevesenet.
- Kontaktpersoner, oppfølgingsplaner og rettigheter må legges frem som en del av utskrivningen. Det må være tydelig hva pasienten selv er ansvarlig for å følge opp – og hva som vil bli fulgt opp av andre ressurspersoner.
- All.Can Norge ønsker en raskere avklaring og konkretisering ifm. arbeidet med «Pakkeforløp, kreftpasienter hjem».
- All.Can ønsker at ordningen med kreftkoordinator skal utvikles og videreføres som en del av det offentlige oppfølgingsansvaret.



# Poland

## Achievements 2020

In early 2020, All.Can Poland created the Presidium, a new body composed of two clinicians, two patient organisation representatives and two industry partners, to improve the National Initiative's effectiveness.

All.Can Poland compiled and disseminated materials for cancer patients during the COVID-19 pandemic, including press releases with guidance from top oncologists calling upon support for patients to continue their treatment or seek diagnosis while the health crisis persists. A short film, "Cancer patients in the time of COVID", was published on the All.Can Poland website and disseminated amongst patient organisations.

In addition, the report "Diagnosis of changes in oncology care in Poland in 2020", analysing achievements, challenges and unmet needs, was published and disseminated widely, and presented to Polish policymakers.


## Outlook 2021

All.Can Poland plans to promote the key findings and recommendations of two reports prepared at the end of

2020 to stakeholders and policymakers at conferences and workshops organised throughout the year.

To promote positive changes in the organisation of oncological care, All.Can Poland supports the project "Standards of patient service as part of the treatment in breast cancer units". Aiming to map diagnosis and treatment processes and introduce actions that lead to more efficient use of resources and better patient outcomes, the project was presented at two workshops in late 2020, and the report and findings will be disseminated in 2021.

The report "Optimising the financing model of diagnosis and treatment in terms of the patient's path and the results of treatment basing on lung cancer" will be launched in early 2021. It will deliver an analysis of the current model of lung cancer diagnosis and treatment and provide suggestions on changes necessary to improve their effectiveness.





# Spain

## Achievements 2020

In early 2020, All.Can Spain's activities were presented in an event at the European Parliament held under the patronage of Dolors Montserrat, MEP. All.Can Spain's representative Enric Barba shared the main goals and achievements of the programme with the audience.

## Outlook 2021

All.Can Spain's main focus during the first months of the year will be to communicate about the work of the network, to generate awareness about the need of efficiency of cancer care and to position cancer as a priority on the Spanish policy agenda, both at regional and national level.

In addition, All.Can Spain will work to initiate debate about the impact of the COVID-19 pandemic on cancer care, and how solutions can be implemented to improve the situation.

All.Can Spain will also establish an online presence and seek to grow the community, planning the launch of an All.Can channel on social media platforms which will provide further visibility to the initiative.







## Sweden

### Achievements 2020

All.Can Sweden was formally re-launched in 2020 with a new Steering Committee. The re-launch took place in December with a two-hour webinar consisting of three parts, as well as introductions from the Steering Committee and a welcome note by Alex Filicevas, President of All.Can International.

The focus of the webinar was to highlight three different groups that are not often talked about: young people with cancer, the homeless and other socially vulnerable people, and immigrants. Representatives of Kvarntorpet, a shelter for homeless run by the charity "Stockholm Stadsmission", of the organization Young Cancer and of the Regional Government-led Cancer Centre in Stockholm were invited to present and provide insights on how these three specific groups experience diagnosis, treatment, and life with cancer.

### Outlook 2021

All.Can Sweden will focus on three main areas in 2021: equal access to cancer care, stigmatisation of cancer patients, and good quality of life for survivors. A number of seminars, including a high-level policy meeting, will be organised during the year.

A survey is currently being conducted among cancer patients, with the results expected to provide insights and information on how Swedish cancer patients view their cancer treatment and quality of life.



# Switzerland

## Achievements 2020

All.Can Switzerland conducted a 'needs assessment' study carried out by the University of Geneva, to analyse the needs of patients and healthcare professionals along the cancer care pathway in order to ensure best care. The roll-out of the results, including a workshop with key stakeholders, as well as a publication in the European Cancer Journal, is planned for early 2021.

A new project focusing on establishing a 'nurse-led clinic' in an outpatient oncology network in the canton of Grisons, a rural area in Switzerland, is being supported by All.Can Switzerland. Planned to start in 2021, the goal is that nurse-guided consultations of outpatients and oncological patients take place in defined patient groups.

Furthermore, All.Can Switzerland began discussions with renowned doctors from the Inselspital Bern about ways to support their multidisciplinary consultations for childhood-cancer survivors, which are the first that systematically implement international recommendations in a multidisciplinary team and aim to provide lifelong care.

Several meetings were held with interested stakeholders and a virtual roundtable was organised with the aim to make All.Can and its activities more visible. As a result, several new members from various fields were welcomed into the network.

## Outlook 2021:

All.Can Switzerland, an independent not-for-profit organisation, will continue to engage with new members and stakeholders through regular Steering group and Board meetings and the General Assembly. A series of workshops including an FMC Workshop on value-based healthcare, a Needs Assessment Workshop with key stakeholders and a Stakeholder Workshop with interested potential members will be organised.

The results of the study on cancer care in Central Switzerland, a project started in July 2018 to identify and leverage potential in regional cancer care, will be presented and disseminated, and at least one new project will be implemented in 2021.

# United Kingdom



## Achievements 2020

To gain a deeper understanding of the inefficiencies in cancer care, All.Can UK developed the report, 'All.Can UK: Placing the psychological wellbeing of people with cancer on equal footing to physical health'. Successfully launched in December and framed within an ongoing campaign "Cancer: Out Of Sight Not Out Of Mind", the report calls on government, policymakers, the NHS, patient organisations, and industry to work with All.Can UK to ensure the psychological wellbeing of people with cancer is placed on an equal footing to their physical health.


A digital toolkit composed of the report, a messaging and guidance document, an infographic, and a pledge card, was developed to support members in driving stakeholder interest via their own digital channels and to drive ongoing commitments to the recommendations.

## Outlook 2021:

Throughout 2021, All.Can UK will use the report and its recommendations as the focus for activity to drive change to improve the situation for cancer patients and their mental health.

Activities will include a targeted policy engagement programme focused on key decision makers and influencers in government and Parliament, NHS system leaders and a broader coalition of patient groups, further expansion of All.Can UK, as well as the development of a video to amplify the patient voice and drive additional social media content around the report's recommendations.

Mapping the services and mental health support options offered by Working Group members will be shared as a resource for clinicians and patients – with the exploration of a partnership with a psychological wellbeing app developer to create an additional platform for people with cancer.



**Join us. Work with us. Together, we All.Can.**

All.Can International  
Rue du Luxembourg 22-24  
1000 Brussels  
Belgium

[secretariat@all-can.org](mailto:secretariat@all-can.org)  
[www.all-can.org](http://www.all-can.org)

Twitter: [@AllCanGroup](https://twitter.com/AllCanGroup)  
LinkedIn: [All.Can](https://www.linkedin.com/company/all-can)  
Facebook: [@AllCanGroup](https://www.facebook.com/AllCanGroup)

All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol Myers Squibb (main sponsor), Roche (major sponsor), MSD and Johnson & Johnson (sponsors) and Baxter and Illumina (contributors), with additional non-financial (in kind) support from Helpsy, Intacare and Goings-On.

